Abstract | BACKGROUND: Endogenous nitric oxide (NO) is beneficial for inhibiting Rho-associated kinase 2 (ROCK2) expression. However, the effect of exogenous NO on ROCK2 expression is less investigated. METHODS: RESULTS: No significant difference in parameters was found between groups at baseline. With 2 weeks of dyslipidemia establishment, as compared to baseline, serum levels of lipid profiles, CRP and MDA were profoundly elevated. In addition, reduced NO generation and enhanced ROCK2 expression were also observed. With 2 weeks of medication therapy, lipid profiles, systemic inflammation (reflected as serum CRP level) and oxidation (reflected as serum MDA level) were improved in the atorvastatin and combined groups but not in the nitroglycerin group (P<0.05). Furthermore, increased NO production in accompany with reduced ROCK2 expression were observed in both the atorvastatin and nitroglycerin groups, and these benefits were further enhanced by combined therapy (P<0.05). No liver enzymes elevation was observed after 2 weeks of medication therapy. CONCLUSION:
|
Authors | Fang Yang, Jindong Wang, Fei Li, Lei Cui |
Journal | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
(Exp Clin Endocrinol Diabetes)
Vol. 124
Issue 6
Pg. 367-71
(Jun 2016)
ISSN: 1439-3646 [Electronic] Germany |
PMID | 27328402
(Publication Type: Journal Article)
|
Copyright | © Georg Thieme Verlag KG Stuttgart · New York. |
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Vasodilator Agents
- Nitric Oxide
- Atorvastatin
- rho-Associated Kinases
- Nitroglycerin
|
Topics |
- Animals
- Atorvastatin
(administration & dosage, pharmacology)
- Disease Models, Animal
- Drug Therapy, Combination
- Dyslipidemias
(drug therapy)
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage, pharmacology)
- Male
- Nitric Oxide
(metabolism)
- Nitroglycerin
(administration & dosage, pharmacology)
- Rabbits
- Vasodilator Agents
(administration & dosage, pharmacology)
- rho-Associated Kinases
(metabolism)
|